Treatment agent for epidermolysis bullosa
AssigneesNational University Corporation Hokkaido University, Life Science Institute, Inc.
InventorsHiroshi SHIMIZU, Yasuyuki FUJITA, Naoya MASUTOMI
Life of this patent
Estimating the term…
Abstract
A cell product for treatment of epidermolysis bullosa, comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell. Preferably, the epidermolysis bullosa is epidermolysis bullosa simplex, junctional epidermolysis bullosa, or dystrophic epidermolysis bullosa.
Claims11
A method for treatment of epidermolysis bullosa, comprising administering an effective amount of a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell to a patient in need thereof.
A skin cell differentiated from a SSEA-3-positive pluripotent stem cell derived from a mesenchymal tissue in a living body or a cultured mesenchymal cell.
Dependencies are inferred from the claim text.